论文部分内容阅读
目的探讨人自体肝癌细胞裂解物致敏的树突状细胞(D C)瘤苗预防肝癌术后转移复发的价值。方法从肝癌患者外周血单核细胞中诱导D C,用重组人粒细胞-巨噬细胞集落刺激因子(rhGM-CSF) 和重组人白细胞介素-4(rhIL-4)刺激活化,经自体肝癌细胞裂解物致敏D C制备瘤苗。将3 0例肝癌术后患者随机分为D C瘤苗治疗组1 5例,对照组1 5例。对两组病例治疗前后免疫功能、临床疗效、肿瘤转移复发率及生存率进行观察比较。结果DC瘤苗治疗后外周血CD 3+、CD4+/CD 8+及自然杀伤细胞比率较治疗前明显升高(P<0.0 5),且明显高于对照组治疗后的相应水平(P<0.05)。DC瘤苗治疗后血清IL-1 0水平明显下降(P<0.0 5)。随访18个月,DC瘤苗治疗组的转移复发率为13.3 3%,明显低于对照组53.33%(P <0.05);而治疗组的生存率为93.33%,明显高于对照组60.00%(P<0.05)。结论肝癌术后行自体肝癌细胞裂解物致敏的DC瘤苗治疗,可改善患者的免疫功能,降低肿瘤转移复发率,提高患者术后生存率,为肝癌的免疫治疗开辟一条新途径。
Objective To investigate the value of dendritic cells (DC) primed by autologous hepatocarcinoma cell lysate in preventing postoperative metastasis and recurrence of liver cancer. Methods DCs were induced from peripheral blood mononuclear cells of patients with hepatocellular carcinoma and activated by recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) and recombinant human interleukin-4 (rhIL-4) Lysates sensitized DC preparation of tumor vaccine. Thirty patients with postoperative liver cancer were randomly divided into Dc tumor vaccine treatment group 15 cases, control group 15 cases. Before and after treatment of two groups of patients with immune function, clinical efficacy, recurrence rate of tumor metastasis and survival were observed and compared. Results The percentage of CD3 +, CD4 + / CD8 + and NK cells in peripheral blood of DC vaccine group was significantly higher than that before treatment (P <0.05), and significantly higher than that of the control group after treatment (P <0.05 ). The level of serum IL-10 after DC vaccine treatment was significantly decreased (P <0.05). The 18-month follow-up showed that the recurrence rate of the DC tumor vaccine group was 13.3 3%, significantly lower than that of the control group (53.33%, P <0.05), while the survival rate of the treatment group was 93.33%, significantly higher than that of the control group 60.00% P <0.05). Conclusion The treatment of DC tumor cells sensitized with autologous liver cancer cell lysate after liver cancer therapy can improve the immune function, reduce the recurrence rate of tumor metastasis, and improve the postoperative survival rate of patients with hepatocellular carcinoma, thus opening up a new way for the immunotherapy of liver cancer.